Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Multi-target peptide vaccine is a preclinical therapeutic cancer vaccine candidate under development by Hebei Bio-High Technology Development, in collaboration with Jiuzhou Pharmaceutical and the research team of Professor Yu Jun at The Chinese University of Hong Kong. The vaccine is designed to target gastrointestinal tumors by incorporating multiple tumor-associated peptide antigens intended to stimulate a specific anti-tumor immune response. The program is currently in the preclinical stage, focusing on identifying and validating optimal peptide targets for gastrointestinal malignancies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on multi-target peptide vaccine.